DeepMed Research

Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: everolimus

First Posted Date: 2009-09-14

Last Posted Date: 2019-08-09

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 37

Registration Number: NCT00976755

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 9 locations

External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: sorafenib tosylate
Radiation: radiation therapy

First Posted Date: 2009-03-26

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 54

Registration Number: NCT00869570

Locations: 🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland
🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 15 locations

Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: panitumumab
Drug: capecitabine
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2008-12-25

Last Posted Date: 2014-04-30

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 68

Registration Number: NCT00814619

Locations: 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭
City Hospital Triemli, Zurich, Switzerland
🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland

and more 21 locations

Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Liver Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Radiation: stereotactic body radiation therapy

First Posted Date: 2008-10-22

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 18

Registration Number: NCT00777894

Locations: 🇳🇱
Maastro Lab at University of Maastricht, Maastricht, Netherlands
🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭
Kantonsspital Aarau, Aarau, Switzerland

and more 3 locations

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: azacytidine

First Posted Date: 2008-08-21

Last Posted Date: 2013-04-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 47

Registration Number: NCT00739388

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

and more 8 locations

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: cetuximab
Drug: docetaxel

First Posted Date: 2008-08-06

Last Posted Date: 2019-05-14

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 35

Registration Number: NCT00728663

Locations: 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
AndreasKlinik Cham Zug, Cham, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland

and more 18 locations

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: dasatinib

First Posted Date: 2007-12-06

Last Posted Date: 2019-06-17

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 47

Registration Number: NCT00568750

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷
Hopital Edouard Herriot - Lyon, Lyon, France

and more 15 locations

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: bevacizumab
Drug: temozolomide

First Posted Date: 2007-12-05

Last Posted Date: 2013-04-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 62

Registration Number: NCT00568048

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Phase 3

Terminated

Conditions: Colorectal Cancer

Interventions: Other: no maintenance
Biological: bevacizumab

First Posted Date: 2007-10-16

Last Posted Date: 2020-02-20

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 265

Registration Number: NCT00544700

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Kantonsspital Bruderholz, Bruderholz, Switzerland

and more 26 locations

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Procedure: positron emission tomography

First Posted Date: 2007-10-16

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 156

Registration Number: NCT00544219

Locations: 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Bruderholz, Bruderholz, Switzerland
🇨🇭
Kantonsspital Liestal, Liestal, Switzerland

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy